Pediatric Nephrology

, Volume 22, Issue 7, pp 981–986 | Cite as

Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy

  • David Askenazi
  • Barry Myones
  • Ankur Kamdar
  • Robert Warren
  • Maria Perez
  • Marietta De Guzman
  • Anna Minta
  • M. John Hicks
  • Arundhati Kale
Original Article


Outcomes in children with proliferate lupus nephritis (PLN) show 9–15% progress to end-stage renal disease (ESRD) at 5 years. Immunosuppression improves outcome, but significant side effects are possible. Clinical and laboratory analyses are poor predictors of class and progression in PLN. We describe 28 patients with systemic lupus erythematosus (SLE), between 1990 and 2005, whose initial biopsy (Bx1) showed PLN and who received nine monthly doses of intravenously administered cyclophosphamide (CYP) (500–750 mg/m2 up to 1 g to maintain their absolute neutrophil count (ANC) > 3,000). Continued therapy with additional quarterly intravenous (i.v). administration of CYP was dictated by repeat renal biopsy (Bx2). Bx1 was done 1 ± 1.6 years after diagnosis of SLE. Bx2 showed histological improvement by WHO classification in 20/25 children; 3/25 were unchanged, 1/25 was categorized as new class V, and 1/25 was worse. Four patients (14%) had infectious complications requiring hospitalization (one of these died). Mean follow-up (f/u) after Bx2 was 3.5 ± 2.3 years. At last follow-up, 26 patients had normal glomerular filtration rate (GFR), with a mean of 126 ± 42.8 ml/min per 1.73 m2 body surface area, one non-compliant patient had ESRD, and one had chronic renal failure. At last follow-up, most patients had minimal to no proteinuria. Clinical and biopsy results greatly improved after 9 monthly intravenously administered CYP pulses in most children with class IV PLN. Those who did not improve are at risk for flares and progression of disease. The tailoring of therapies based on findings from a biopsy after induction may improve outcomes.


Lupus nephritis Proliferative Protocol biopsy Cyclophosphamide Outcome 


  1. 1.
    Austin HA 3rd, Klippel JH, Balow JE, le Richie NG, Steinberg AD, Poltz PH, Decker JL (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619PubMedCrossRefGoogle Scholar
  2. 2.
    Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM (1978) Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299:1151–1155PubMedCrossRefGoogle Scholar
  3. 3.
    Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241–250PubMedCrossRefGoogle Scholar
  4. 4.
    Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945–950PubMedCrossRefGoogle Scholar
  5. 5.
    Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A (1996) Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 7:924–929PubMedGoogle Scholar
  6. 6.
    Bogdanovic R, Nikolic V, Pasic S, Dimitrijevic J, Lipkovska-Markovic J, Eric-Marinkovic J, Ognjanovic M, Minic A, Stajic N (2004) Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol 19:36–44PubMedCrossRefGoogle Scholar
  7. 7.
    Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E (2002) Longterm followup of childhood lupus nephritis. J Rheumatol 29:2635–2642PubMedGoogle Scholar
  8. 8.
    McCurdy DK, Lehman TJ, Bernstein B, Hanson V, King KK, Nadorra R, Landing BH (1992) Lupus nephritis: prognostic factors in children. Pediatrics 89:240–246PubMedGoogle Scholar
  9. 9.
    Niaudet P (2000) Treatment of lupus nephritis in children. Pediatr Nephrol 14:158–166PubMedCrossRefGoogle Scholar
  10. 10.
    Yang LY, Chen WP, Lin CY (1994) Lupus nephritis in children—a review of 167 patients. Pediatrics 94:335–340PubMedGoogle Scholar
  11. 11.
    Barbano G, Gusmano R, Damasio B, Alpigiani MG, Buoncompagni A, Gattorno M, Perfumo F (2002) Childhood-onset lupus nephritis: a single-center experience of pulse intravenous cyclophosphamide therapy. J Nephrol 15:123–129PubMedGoogle Scholar
  12. 12.
    De Bandt M, Goycochea MV, Meyer O, Delahousse M, Palazzo E, M’Bappe P, Kahn MF (1994) Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide. Value and limitations. Ann Med Interne (Paris) 145:75–87Google Scholar
  13. 13.
    Gladman DD, Urowitz MB, Cole E, Ritchie S, Chang CH, Churg J (1989) Kidney biopsy in SLE. I. A clinical-morphologic evaluation. Q J Med 73:1125–1133PubMedGoogle Scholar
  14. 14.
    Pillemer SR, Austin HA 3rd, Tsokos GC, Balow JE (1988) Lupus nephritis: association between serology and renal biopsy measures. J Rheumatol 15:284–288PubMedGoogle Scholar
  15. 15.
    Gunnarsson I, Sundelin B, Heimburger M, Forslid J, van Vollenhoven R, Lundberg I, Jacobson SH (2002) Repeated renal biopsy in proliferative lupus nephritis—predictive role of serum C1q and albuminuria. J Rheumatol 29:693–699PubMedGoogle Scholar
  16. 16.
    Hill GS, Delahousse M, Nochy D, Remy P, Mignon F, Mery JP, Bariety J (2001) Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 59:304–316PubMedCrossRefGoogle Scholar
  17. 17.
    Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMedGoogle Scholar
  18. 18.
    Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarin M (1989) The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 72:779–833PubMedGoogle Scholar
  19. 19.
    Levey AS, Lan SP, Corwin HL, Kasinath BS, Lachin J, Neilson EG, Hunsicker LG, Lewis EJ (1992) Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 116:114–123PubMedGoogle Scholar
  20. 20.
    Moroni G, Pasquali S, Quaglini S, Banfi G, Casanova S, Maccario M, Zucchelli P, Ponticelli C (1999) Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 34:530–539PubMedGoogle Scholar
  21. 21.
    Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C (1996) “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 50:2047–2053PubMedCrossRefGoogle Scholar
  22. 22.
    Ponticelli C, Moroni G (1998) Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus 7:635–638PubMedCrossRefGoogle Scholar
  23. 23.
    Lenz O, Fornoni A, Contreras G (2006) New directions in the management of severe lupus nephritis. Minerva Urol Nefrol 58:29–38PubMedGoogle Scholar
  24. 24.
    Robak E, Sysa-Jedrzejowska A, Wozniacka A (2005) Progress and perspectives in the treatment of systemic lupus erythematosus. Przegl Lek 62:894–899PubMedGoogle Scholar

Copyright information

© IPNA 2007

Authors and Affiliations

  • David Askenazi
    • 1
  • Barry Myones
    • 2
  • Ankur Kamdar
    • 2
  • Robert Warren
    • 2
  • Maria Perez
    • 2
  • Marietta De Guzman
    • 2
  • Anna Minta
    • 2
  • M. John Hicks
    • 3
  • Arundhati Kale
    • 2
  1. 1.Department of PediatricsUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Pediatric RheumatologyTexas Children’s HospitalHoustonUSA
  3. 3.Department of PathologyBaylor College of MedicineHoustonUSA

Personalised recommendations